In this article, we discuss the 5 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 12 Best Day Trading Stocks To Buy.
5. HUB Cyber Security Ltd. (NASDAQ:HUBC)
Number of Hedge Fund Holders: 6
Average Trading Volume as of November 2: 19.7 Million
Share Price Gain in Past Month: 228%
HUB Cyber Security Ltd. (NASDAQ:HUBC) provides cyber security solutions. Some of the products it markets include HUB Secure File Vault, a super charged file transfer backed by dedicated hardware driven security, HUB Guard, a recurring security assessment, continuous network, and infrastructure monitoring and analysis, D.Storm, a powerful simulation platform, and RAM Commander, a software tool for reliability prediction and analysis, reliability block diagram, Markov chains analysis, maintainability prediction, and spares optimization.
On October 31, HUB Cyber Security Ltd. (NASDAQ:HUBC) announced that it had entered into a strategic alliance with an unnamed company in the field of automation of cyber risk detection and response.
At the end of the second quarter of 2023, 7 hedge funds in the database of Insider Monkey held stakes worth $63,000 in HUB Cyber Security Ltd. (NASDAQ:HUBC), compared to 6 in the preceding quarter worth $106,000.
4. Tempest Therapeutics, Inc. (NASDAQ:TPST)
Number of Hedge Fund Holders: 6
Average Trading Volume as of November 2: 19.35 Million
Share Price Gain in Past Month: 1,093%
Tempest Therapeutics, Inc. (NASDAQ:TPST) is a clinical-stage oncology company that develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. Lead product candidates of the firm are TPST-1495 and TPST-1120. Both are in Phase 1 trial for the treatment of solid tumors. The company is based in Brisbane, California. The stock has rallied in the past few weeks after the firm released positive data from the trials for TPST-1120.
On October 11, HC Wainwright analyst Joseph Pantginis maintained a Buy rating on Tempest Therapeutics, Inc. (NASDAQ:TPST) stock and raised the price target to $47 from $35, noting that the data positions the firm strongly to add quite meaningful to the standard of care regiment in first-line hepatocellular carcinoma.
At the end of the second quarter of 2023, 6 hedge funds in the database of Insider Monkey held stakes worth $2,915,000 in Tempest Therapeutics, Inc. (NASDAQ:TPST), compared to 4 in the previous quarter worth $4,364,000.
3. BioXcel Therapeutics, Inc. (NASDAQ:BTAI)
Number of Hedge Fund Holders: 6
Average Trading Volume as of November 2: 4.6 Million
Share Price Gain in Past Month: 80%
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a commercial-stage biopharmaceutical company that engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The stock has gained in the past few weeks after the firm announced that the Centers for Medicare & Medicaid Services had granted a permanent and product-specific J-code for Igalmi, a psychiatric therapy being developed by the firm. J-codes are used by government and commercial health insurers to simplify and streamline billing and reimbursement of Medicare Part B drugs administered at outpatient facilities.
On August 18, investment advisory HC Wainwright maintained a Buy rating on BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stock and lowered the price target to $11 from $60, citing second quarter results and revenue forecast downgrades.
Among the hedge funds being tracked by Insider Monkey, Florida-based investment firm Citadel Investment Group is a leading shareholder in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) with 98,800 shares worth more than $658,000.
At the end of the second quarter of 2023, 6 hedge funds in the database of Insider Monkey held stakes worth $15 million in BioXcel Therapeutics, Inc. (NASDAQ:BTAI), compared to 7 in the previous quarter worth $53 million.
2. Tupperware Brands Corporation (NYSE:TUP)
Number of Hedge Fund Holders: 9
Average Trading Volume as of November 2: 6.62 Million
Share Price Gain in Past Month: 26%
Tupperware Brands Corporation (NYSE:TUP) operates as a consumer products company worldwide. The areas in which it operates include the Asia Pacific, Europe, Africa, the Middle East, North America, and South America. Some of the products it sells include cookware, knives, microwave products, microfiber textiles, water-filtration related items, and an array of products for on-the-go consumers under the Tupperware brand name. The company is based in Florida and was founded in 1946.
Tupperware Brands Corporation (NYSE:TUP) stock has rallied in the past few weeks, even though the short interest on the shares is high, after the company disclosed in a SEC filing that it entered into the fifth amendment to an existing credit agreement that extended the deadline for delivery of the annual audited financial statements from September 16 to November 1.
At the end of the second quarter of 2023, 9 hedge funds in the database of Insider Monkey held stakes worth $3.8 million in Tupperware Brands Corporation (NYSE:TUP), compared to 20 in the preceding quarter worth $16 million.
Among the hedge funds being tracked by Insider Monkey, Florida-based investment firm Citadel Investment Group is a leading shareholder in Tupperware Brands Corporation (NYSE:TUP) with 569,100 shares worth more than $455,000.
1. Nkarta, Inc. (NASDAQ:NKTX)
Number of Hedge Fund Holders: 12
Average Trading Volume as of November 2: 4.8 Million
Share Price Gain in Past Month: 45%
Nkarta, Inc. (NASDAQ:NKTX) is a clinical-stage biopharmaceutical company that develops and commercializes cell therapies for cancer treatment. The firm focuses on cellular immunotherapy that involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Lead product candidates include NKX101 and NKX019. The shares have climbed in the past few weeks after the firm revealed that drug agencies had approved Phase 1 testing of NKX019 for lupus nephritis. The firm also said it was cutting costs to extend the cash runway into 2026.
On October 18, HC Wainwright analyst Emily Bodnar maintained a Buy rating on Nkarta, Inc. (NASDAQ:NKTX) stock and lowered the price target to $10 from $16, noting that a lot of uncertainty persists as the company optimizes doses and dosing regimens for new drugs.
Among the hedge funds being tracked by Insider Monkey, Boston-based investment firm RA Capital Management is a leading shareholder in Nkarta, Inc. (NASDAQ:NKTX) with 7.8 million shares worth more than $17 million.
At the end of the second quarter of 2023, 12 hedge funds in the database of Insider Monkey held stakes worth $30 million in Nkarta, Inc. (NASDAQ:NKTX), compared to 17 in the previous quarter worth $59 million.
You can also take a peek at 12 Countries That Produce The Best Cosmetics and Top 15 3D Companies in the World.
